Septerna, Inc. (NASDAQ:SEPN) Director Purchases $47,567.85 in Stock

Septerna, Inc. (NASDAQ:SEPN - Get Free Report) Director Alan Ezekowitz bought 7,491 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were bought at an average price of $6.35 per share, for a total transaction of $47,567.85. Following the completion of the transaction, the director now directly owns 24,911 shares of the company's stock, valued at $158,184.85. This represents a 43.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Alan Ezekowitz also recently made the following trade(s):

• On Thursday, March 6th, Alan Ezekowitz acquired 41,355 shares of Septerna stock. The stock was bought at an average cost of $6.00 per share, for a total transaction of $248,130.00.

Septerna Stock Down 8.7 %

SEPN stock traded down $0.56 during trading on Monday, hitting $5.87. 769,009 shares of the company's stock traded hands, compared to its average volume of 590,636. The stock's fifty day moving average price is $14.10. Septerna, Inc. has a 1 year low of $4.17 and a 1 year high of $28.99.

Hedge Funds Weigh In On Septerna

Hedge funds and other institutional investors have recently bought and sold shares of the business. RA Capital Management L.P. acquired a new position in shares of Septerna in the fourth quarter worth about $160,205,000. TRV GP V LLC purchased a new stake in Septerna in the 4th quarter valued at $142,337,000. TRV GP VI LLC purchased a new stake in shares of Septerna in the 4th quarter valued at approximately $72,191,000. Samsara BioCapital LLC purchased a new stake in Septerna in the fourth quarter valued at $63,399,000. Finally, Driehaus Capital Management LLC purchased a new stake in shares of Septerna in the 4th quarter valued at approximately $59,301,000.

Remove Ads

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. TD Cowen began coverage on shares of Septerna in a report on Tuesday, November 19th. They issued a "buy" rating for the company. JPMorgan Chase & Co. began coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued an "overweight" rating and a $38.00 price objective for the company. Wells Fargo & Company cut shares of Septerna from an "overweight" rating to an "equal weight" rating and lowered their target price for the company from $43.00 to $14.00 in a research note on Tuesday, February 18th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $50.00 price target on shares of Septerna in a report on Tuesday, February 11th.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.